

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune	IgG	<p><i>In vitro</i> and mouse studies suggest that trisubstituted triazines that bind IgG could help treat autoimmune disease. Synthesis and <i>in vitro</i> testing of a series of 2,4,6-trisubstituted triazines identified a lead compound (PBI-1308) with low nanomolar affinity for IgG. In two mouse models of systemic lupus erythematosus (SLE), PBI-1308 reduced disease symptoms compared with no treatment. Next steps include follow-on studies in animal models of other autoimmune diseases.</p> <p>SciBX 3(3); doi:10.1038/scibx.2010.77 Published online Jan. 21, 2010</p>	<p>Patented by ProMetic BioSciences Inc., a subsidiary of ProMetic Life Sciences Inc.; ProMetic has partnered with Laboratorios Dermatológicos Darier S.A. de C.V. to develop PBI-1308 to treat dermatological indications; available for partnering or licensing to treat other indications</p>	<p>Zacharie, B. <i>et al. J. Med. Chem.</i>; published online Jan. 4, 2010; doi:10.1021/jm901403r Contact: Boulos Zacharie, ProMetic Life Sciences Inc., Montreal, Quebec, Canada e-mail: b.zacharie@prometic.com</p>